eli lilly and tirzepatide weight loss drug data released FDA approves tirzepatide, Eli Lilly's

FGF21 (NCT03976401), FGF19 (NCT03912532), obeticholic acid (NCT01265498, T02548351), pioglitazone (NCT00994682, NCT00063622, NCT00062764, CT00227110), semaglutide (NCT02970942), and resmetirom (NCT02912260) had significant effects on NASH patients (Table 2)

Safety - May be safer than other options due to its unique mechanism

Ginger tea, peppermint, and acupressure wristbands offer additional relief for some patients

Long-Term Management Strategies Long-term management focuses on preventing future episodes

The top three SOCs were injury, poisoning and procedural complications (n = 23,918), general disorders and administration site conditions (n = 21,240), and gastrointestinal disorders (n = 14,934)